Interventional Glaucoma

The company anticipates introducing latanoprost ophthalmic solution 0.005% to U.S. eye care practitioners in the second half of 2023.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

A new device for goniotomy has the advantage of an irrigation/aspiration system, which offers easier excision of the trabecular meshwork and better visibility. Dr Desai shares his experiences using the device as well as his tips and surgical pearls for success.

Studies reveal the advantages of numerous new glaucoma treatments that offer a wider range of options for individual patients.

Combining ECP with vitrectomy can reduce medication use following the procedure and in some cases avoid the need for further surgery.

An end-of-week review of what happened in ophthalmology from 29 October to 3 November 2022.

Gentle eye drops, laser or minimally invasive surgery, advising patients on safe viewing of electronic devices, and addressing eyelid disorders can all help to minimise adverse effects.

Investigators report that a gel-forming sustained-delivery eye drop containing sunitinib can provide increased intraocular absorption of the drug while protecting retinal cells.

Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.

The goal of World Sight Day, according to IAPB, is “to shine a light on blindness and vision impairment as a major, but solvable, public health issue."

At AAO 2022, Dr Mitch Shultz provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

A combination of posters, podium presentations and instructional courses provided invaluable revelations to the ophthalmic community.

Robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.

13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).

Following the lockdown due to COVID-19, investigators highlight the need to re-assess policies on patient follow-up and establish new approaches to provision of care for elderly patients.

Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."

According to Nicox SA, the patients made their final 3-month visit last week. Top line results of the trial are expected in November.

Dr David Lubeck talks with Caroline Richards of Ophthalmology Times Europe about his ESCRS presentations, touching on surgical effects on corneal epithelium and the iTrack Global Registry for glaucoma.

The investigators explained that elevated angle-closure-related intraocular pressure may aggregate the visual impairment in patients with retinitis pigmentosa.

Physicians may need to recognize issues and treat patients more holistically.

Although the standard of care remains the pharmaceutical option, surgeons would like to see other options for individualised treatment, including artificial intelligence and sustained-release technologies.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and side effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study. This measurement could potentially be used as a first-line indicator to monitor of glaucoma progression for the patient and the physician.

The lower energy applications and slower sweep speeds offer marked IOP reductions in patients.